125 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
21 Recruiting Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Recurrent Glioblastoma;   Recurrent Adult Brain Tumor;   Gliosarcoma
Interventions: Biological: HSPPC-96;   Drug: bevacizumab
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH / Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 165
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01814813
22 Recruiting Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 400
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01617161
23 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 880
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01242800
24 Recruiting Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 240
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01124695
25 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 250
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT01000753
26 Recruiting BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Biological: emepepimut-S;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Radiation: radiation therapy
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 55
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00828009
27 Unknown  Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT00897767
28 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib Hydrochloride;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 234
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01822496
29 Recruiting Mobile Health Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors
Conditions: Survivorship;   Fatigue
Interventions: Behavioral: Exercise Intervention;   Behavioral: Internet-Based Intervention;   Device: Monitoring Device;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 108
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT02688192
30 Recruiting Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Conditions: Stage II Non-Small Cell Lung Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pembrolizumab
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH / Industry
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 30
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02621398
31 Recruiting Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Conditions: Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Procedure: Arterial Spin Labeling Magnetic Resonance Imaging;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Perfusion Magnetic Resonance Imaging
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Diagnostic;   Masking: Open Label
Number Enrolled: 50
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02526511
32 Recruiting Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer
Interventions: Radiation: Accelerated Partial Breast Irradiation;   Radiation: High-Dose Rate Brachytherapy;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 200
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT02526498
33 Recruiting Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Conditions: Metastatic Prostate Carcinoma;   Metastatic Prostatic Adenocarcinoma;   Prostate Carcinoma Metastatic to the Bone
Interventions: Procedure: Robotic Assisted Radical Prostatectomy;   Procedure: Conventional open retropubic radical prostectomy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 50
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT02458716
34 Recruiting Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
Conditions: Recurrent Prostate Carcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Placebo
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject, Investigator)
Number Enrolled: 66
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT02420652
35 Recruiting Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor
Interventions: Drug: Oral ONC201;   Other: pharmacological study;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH / Industry
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 30
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02324621
36 Recruiting Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
Conditions: Recurrent Skin Cancer;   Squamous Cell Carcinoma of the Skin
Interventions: Biological: cetuximab;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 20
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02324608
37 Recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 60
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT02315196
38 Recruiting Oral ONC201 in Treating Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Oral ONC201
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 30
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02250781
39 Recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 82
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02203604
40 Recruiting Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 20
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02203578

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years